



David T Gray, Vice-chair Austin Commission on Seniors  
[davidtgray@austin.rr.com](mailto:davidtgray@austin.rr.com)  
 512-913-0326

## Doping Seniors Antipsychotic and Anti-Seizure Drugs

**DRAFT PROPOSAL** - please edit for our discussion at meetings - add your thoughts and comments. We will need a second to discuss it – it doesn't mean you support it.

**FDA ALERT [6/16/2008]: FDA is notifying healthcare professionals that both conventional and atypical **ANTIPSYCHOTICS** are associated with an increased risk of mortality in elderly patients treated for dementia-related psychosis...**

[1] <http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm123246.htm>

- Antipsychotic drugs are not approved for the treatment of dementia-related psychosis. Furthermore, there is no approved drug for the treatment of dementia-related psychosis. Healthcare professionals should consider other management options.

<http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm>

### Senate Special Committee on Aging C-Span Video

<http://www.c-span.org/video/?302927-1/antipsychotic-drug-prescriptions-nursing-homes>




NOV. 4, 2013: Johnson & Johnson has agreed to pay more than \$2.2 billion in criminal and civil fines to settle accusations that it improperly promoted the Antipsychotic drug Risperdal to older adults, children and people with developmental disabilities. <http://www.justice.gov/opa/pr/2013/November/13-ag-1170.html>

The agreement is the third-largest pharmaceutical settlement in United States history and the largest in a string of recent cases involving the marketing of to older dementia patients. It is part of a decade-long effort by the federal government to hold the health care giant — and other pharmaceutical companies — accountable for illegally marketing the drugs as a way to control patients with dementia in nursing homes and children with certain behavioral disabilities, despite the health risks of the drugs.

[http://www.nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html?pagewanted=all&\\_r=1](http://www.nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html?pagewanted=all&_r=1)

## Death In 3 Years

**FDA Black Box Warning of Death for Dementia patients taking Antipsychotic drugs**



Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. [1]

**PROPOSAL:** That the city council undertake a public relations campaign to make Austin an **Antipsychotic** and **Anti-Seizure** prescription drug free environment for seniors in accordance with **FDA guidelines**.